Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Travoprost/timolol eye drop solution (called Travoprost/timolol eye drops throughout this leaflet) is a combination of two active substances (travoprost and timolol). Travoprost is a prostaglandin analogue which works by increasing the outflow of aqueous fluid from the eye, which lowers its pressure. Timolol is a beta blocker which works by reducing the production of fluid within the eye. The two substances work together to reduce pressure within the eye.
Travoprost/timolol eye drops are used to treat high pressure in the eye in adults, including the elderly. This pressure can lead to an illness called glaucoma.
Do not use Travoprost/timolol eye drops • if you are allergic to travoprost, prostaglandins, timolol, beta blockers or any of the other ingredients of this medicine (listed in section 6).
• if you have now or have had in the past respiratory problems such as asthma, severe chronic obstructive bronchitis (severe lung disease which may cause wheeziness, difficulty in breathing and/or long-standing cough), or other types of breathing problems.
• if you have severe hay fever.
• if you have a slow heartbeat, heart failure or a disorder of heart rhythm (irregular heartbeat).
• if the surface of your eye is cloudy.
Ask your doctor for advice if any of these applies to you.
Warning and precautions Talk to your doctor before using Travoprost/timolol eye drops if you have now or have had in the past
• coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure.
• disturbances of heart rate such as slow heartbeat.
• breathing problems, asthma or chronic obstructive pulmonary disease.
• poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome).
• diabetes (as timolol may mask signs and symptoms of low blood sugar).
• overactivity of the thyroid gland (as timolol may mask signs and symptoms of thyroid disease).
• myasthenia gravis (chronic neuromuscular weakness).
• cataract surgery.
• eye inflammation.
If you need to have any type of surgery, tell your doctor that you are using Travoprost/timolol eye drops as timolol may change the effects of some medicines used during anaesthesia.
If you get any severe allergic reaction (skin rash, redness and itching of the eye) while using Travoprost/timolol eye drops, whatever the cause, adrenaline treatment may not be as effective. It is therefore important to tell the doctor that you are using Travoprost/timolol eye drops when you are to receive any other treatment.
Travoprost/timolol may change the colour of your iris (the coloured part of your eye). This change may be permanent.
Travoprost/timolol may increase the length, thickness, colour and/or number of your eyelashes and may cause unusual hair growth on your eyelids.
Travoprost may be absorbed through the skin and therefore should not be used by women who are pregnant or are attempting to become pregnant. If any of the medicine comes into contact with the skin then it should be washed off straight away.
Children Travoprost/timolol eye drops is not to be used by children and adolescents under 18 years of age.
Other medicines and Travoprost/timolol eye drops Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Travoprost/timolol can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. Tell your doctor if you are using or intend to use medicines to lower blood pressure, heart medicines including quinidine (used to treat heart conditions and some types of malaria), medicines to treat diabetes or the antidepressants fluoxetine or paroxetine.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Do not use Travoprost/timolol eye drops if you are pregnant unless your doctor considers it necessary. If you could get pregnant you must use adequate contraception whilst you use the medicine.
Do not use Travoprost/timolol eye drops if you are breast-feeding. Travoprost/timolol may get into your milk.
Driving and using machines You may find that your vision is blurred for a time just after you use Travoprost/timolol eye drops. Travoprost/Timolol eye drops may also cause hallucinations, dizziness, nervousness or fatigue in some patients.
Do not drive or use machines until this has worn off.
Travoprost/timolol eye drops contains macrogolglycerol hydroxystearate which may cause skin reactions.
Travoprost/timolol eye drops contains 0.15 mg benzalkonium chloride per ml which is equivalent to 6 µg benzalkonium chloride per drop (= 1 dose).
Benzalkonium chloride is a preservative which may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards.
Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one drop in the affected eye or eyes once a day in the morning or in the evening. Use at the same time each day.
Only use Travoprost/timolol in both eyes if your doctor told you to do so.
Only use Travoprost/timolol as eye drops.
• Immediately before using a bottle for the first time, write the date of opening on the label in the space provided.
• Make sure you have a mirror available.
• Wash your hands.
• Twist off the bottle cap.
• Hold the bottle, pointing down, between your thumb and fingers.
• Tilt your head back. Pull your lower eyelid down with a clean finger until there is a “pocket” between the eyelid and your eye. The drop will go in here (picture 1).
• Bring the bottle dropper close to the eye. Use the mirror if it helps. (picture 2)
• Do not touch your eye or eyelid, the surrounding areas or other surfaces with the dropper. It could infect the drops.
• Gently squeeze the bottle to release one drop of Travoprost/timolol eye drops at a time (picture 3). If a drop misses your eye, try again.
• After using Travoprost/timolol eye drops, press your finger into the corner of your eye by your nose for 2 minutes (picture 4). This helps to stop Travoprost/timolol eye drops getting into the rest of the body.
• If you have to use Travoprost/timolol eye drops in both eyes, repeat the above steps for your other eye.
• Close the bottle cap firmly immediately after use.
• Only use one bottle at a time.
Use Travoprost/timolol eye drops for as long as your doctor has told you to.
If you use more Travoprost/timolol eye drops than you should If you use more Travoprost/timolol eye drops than you should, rinse it all out with warm water. Do not put in any more drops until it is time for your next regular dose.
If you forget to use Travoprost/timolol eye drops If you forget to use Travoprost/timolol eye drops, continue with the next dose as planned. Do not use a double dose to make up for the forgotten dose. The dose should not exceed one drop daily in the affected eye(s).
If you stop using Travoprost/timolol eye drops If you stop using Travoprost/timolol eye drops without speaking to your doctor the pressure in your eye will not be controlled, which could lead to loss of sight.
If you are using other eye drops in addition to Travoprost/timolol eye drops leave at least 5 minutes between applying Travoprost/timolol eye drops and the other drops.
If you wear soft contact lenses do not use the drops with your lenses in. After using the drops wait 15 minutes before putting your lenses back in.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects although not everybody gets them.
You can usually carry on using the drops, unless the effects are serious. If you are worried, talk to a doctor or pharmacist. Do not stop using Travoprost/timolol eye drops without speaking to your doctor.
Very common side effects (may affect more than 1 in 10 people)
Effects in the eye
Eye redness.
Common side effects (may affect up to 1 in 10 people)
Effects in the eye
Eye surface inflammation with surface damage, eye pain, blurred vision, abnormal vision, dry eye, itchy eye, eye discomfort, signs and symptoms of eye irritation (e.g. burning, stinging).
Uncommon side effects (may affect up to 1 in 100 people)
Effects in the eye
Inflammation of the eye surface, inflammation of the eyelid, swollen conjunctiva, increased growth of eyelashes, iris inflammation, eye inflammation, sensitivity to light, reduced vision, tired eyes, eye allergy, eye swelling, increased tear production, eyelid redness, eyelid colour change, skin darkening (around the eye).
General side effects
Allergic reaction to active substance, dizziness, headache, increased or decreased blood pressure, shortness of breath, excessive hair growth, drip at back of throat, skin inflammation and itching, decreased heart rate.
Rare side effects (may affect up to 1 in 1,000 people)
Effects in the eye
Thinning of the eye surface, inflammation of the eyelid glands, broken blood vessel in the eye, eyelid crusting, abnormally positioned eyelashes, abnormal growth of lashes.
General side effects
Nervousness, irregular heart rate, loss of hair, voice disorders, difficulty breathing, cough, throat irritation, hives, abnormal liver blood tests, skin discolouration, thirst, tiredness, discomfort inside of nose, coloured urine, pain in hands and feet.
Not known (frequency cannot be estimated from the available data)
Effects in the eye
Droopy eyelid (making the eye stay half closed), sunken eyes (eyes appear more inset), changes in the colour of the iris (coloured part of the eye).
General side effects
Rash, heart failure, chest pain, stroke, fainting, depression, asthma, increased heart rate, numbness or tingling sensation, palpitations, swelling in the lower limbs, bad taste.
Additionally:
Travoprost/timolol eye drops is a combination of two active substances, travoprost and timolol. Like other medicines administered to the eyes, travoprost and timolol (a beta blocker) are absorbed into the blood. This may cause side effects similar to those seen when beta-blocking medicines that are administered by mouth or by injection. The incidence of side effects after administration to the eyes is lower than after administration by mouth or by injection.
The side effects listed below include reactions seen with the class of beta blockers used for treating eye conditions or reactions seen with travoprost alone:
Effects in the eye
Inflammation of the eyelid, inflammation in the cornea, detachment of the layer below the retina that contains blood vessels following filtration surgery which may cause visual disturbances, decreased corneal sensitivity, corneal erosion (damage to the front layer of the eyeball), double vision, eye discharge, swelling around the eye, eyelid itching, outward turning of eyelid with redness, irritation and excessive tears, blurred vision (sign of clouding of the eye lens), swelling of a section of the eye (uvea), eczema of the eyelids, halo vision, decreased eye sensation, pigmentation inside the eye, dilatated pupils, change in eyelash colour, change in the texture of the eyelashes, abnormal field of vision.
General side effects
Ear and labyrinth disorders: dizziness with spinning sensation, ringing in the ears.
Heart and circulation: slow heart rate, palpitations, oedema (fluid build-up), changes in heartbeat rhythm or speed, congestive heart failure (heart disease with shortness of breath and swelling of the feet and legs due to fluid build-up), a type of heart rhythm disorder, heart attack, low blood pressure, Raynaud’s phenomenon, cold hands and feet, reduced blood supply to the brain.
Respiratory: constriction of the airways in the lungs (predominantly in patients with pre-existing disease), runny or stuffy nose, sneezing (due to allergy), difficulty breathing, nose bleed, nasal dryness.
Nervous system and general disorders: difficulty sleeping (insomnia), nightmares, memory loss, hallucination, loss of strength and energy, anxiety (excessive emotional distress).
Gastrointestinal: taste disturbances, nausea, indigestion, diarrhoea, dry mouth, abdominal pain, vomiting and constipation.
Allergy: increased allergic symptoms, generalised allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs and can obstruct the airway which may cause difficulty swallowing or breathing, localised and generalised rash, itchiness, severe sudden life-threatening allergic reaction.
Skin: skin rash with white silvery coloured appearance (psoriasiform rash) or worsening of psoriasis, peeling skin, abnormal hair texture, inflammation of the skin with itchy rash and redness, hair colour change, loss of eyelashes, itching, abnormal hair growth, skin redness.
Muscular, increases in signs and symptoms of myasthenia gravis (muscle disorder), unusual sensations like pins and needles, muscle weakness/tiredness, muscle pain not caused by exercise, joint pain.
Renal and urinary disorders. difficulty and pain when passing urine, involuntary leakage of urine,
Reproduction: sexual dysfunction, decreased libido.
Metabolism. low blood sugar levels, increase in prostate cancer marker.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Keep the bottle in the outer carton in order to protect from light.
Do not use this medicine after the expiry date which is stated on the bottle label and carton after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions.
You must throw away the bottle 28 days after you first opened it to prevent the risk of infections.
Each time you start a new bottle write down the date you open it in the spaces on the bottle label and carton.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Travoprost/timolol eye drops contains • The active substances are travoprost and timolol. Each ml of solution contains 40 micrograms of travoprost and 5 mg of timolol (as timolol maleate).
• Each drop contains approximately 1.14 mcg – 1.39 mcg travoprost and 0.14 mg - 0.17 mg timolol.
• The other ingredients are benzalkonium chloride (see section 2), mannitol (E421), trometamol, boric acid, macrogolglycerol hydroxystearate, sodium hydroxide or hydrochloric acid (to adjust pH), disodium edetate, water for injections.
Tiny amounts of sodium hydroxide or hydrochloric acid are added to keep acidity levels (pH levels) normal.
What Travoprost/timolol eye drops looks like and contents of the pack Travoprost/timolol eye drops is a liquid (a clear, colourless solution) supplied in a 5 ml low-density polyethylene (LDPE) bottle with LDPE droppers and HDPE caps. Each bottle contains 2.5 ml solution.
Packs of 1, 3 or 6 bottles.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Zentiva Pharma UK Ltd.
12 New Fetter Lane
London
EC4A 1JP
United Kingdom
Manufacturer RAFARM SA
Thesi Pousi-Xatzi
Agiou Louka
19002
Paiania
Greece
This leaflet was last revised in June 2025
1065040498
Zentiva
Address
First Floor, Andrews House, College Road, Guildford, Surrey, GU1 4QB, UK
Medical Information Direct Line
+44 (0)800 090 2408
Customer Care direct line
+44 (0)844 8793 188
E-mail
[email protected]
WWW
https://www.zentiva.co.uk/contact/mi-form
Medical Information e-mail
[email protected]
• Contact us
• Links
• Accessibility
• Legal and privacy notice
• Cookie notice
• Cookie Settings
• Glossary
• Site Maps
Delivered to you by
Travoprost/Timolol 40 micrograms/ml + 5 mg/ml eye drops, solution 5 mg, 0.04 mg comes as drops containing 40 microgram. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Travoprost/Timolol 40 micrograms/ml + 5 mg/ml eye drops, solution 5 mg, 0.04 mg is timolol maleate.
Medicines with the same active substance include: Eysano 2.5mg/ml Eye Drops, Solution, Eysano 5mg/ml Eye Drops, Solution, TIOPEX timolol 1 mg/g, eye gel in single-dose container, Timolol 0.25% w/v Eye Drops Solution, Timolol 0.5% w/v Eye Drops Solution, Timolol Eye Drops 0.25%. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Travoprost/Timolol 40 micrograms/ml + 5 mg/ml eye drops, solution 5 mg, 0.04 mg, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Travoprost/Timolol is indicated in adults for the decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers or prostaglandin analogues (see section 5.1).
Posology
Use in adults, including the elderly
The dose is one drop of Travoprost/Timolol in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Special populations
Hepatic and renal impairment
No studies have been conducted with the combination travoprost 40 micrograms/ml + timolol 5 mg/ml eye drops, solution or with timolol 5 mg/ml eye drops in patients with hepatic or renal impairment.
Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/min). No dose adjustment was necessary in these patients.
Patients with hepatic or renal impairment are unlikely to require dose adjustment with Travoprost/Timolol (see section 5.2).
Paediatric population
The safety and efficacy of Travoprost/Timolol in children and adolescents below the age of 18 years have not been established. No data are available.
Method of administration
For ocular use.
The patient should remove the protective overwrap immediately prior to initial use. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
When nasolacrimal occlusion is used or the eyelids are closed for 2 minutes, systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4).
If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart (see section 4.5).
When substituting another ophthalmic antiglaucoma medicinal product with Travoprost/Timolol, the other medicinal product should be discontinued and Travoprost/Timolol should be started the following day.
Patients must be instructed to remove soft contact lenses prior to application of Travoprost/Timolol and wait 15 minutes after instillation of the dose before reinsertion (see section 4.4).
Hypersensitivity to the active substances, or to any of the excipients listed in section 6.1.
Hypersensitivity to other beta blockers.
Reactive airway disease including bronchial asthma, or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, including sino-atrial block, second- or third-degree atrioventricular block not controlled with pacemaker. Overt cardiac failure, cardiogenic shock. Severe allergic rhinitis and corneal dystrophies.
No specific drug interaction studies have been performed with travoprost or timolol.
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blocker solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics or guanethidine.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta blockers.
Potentiated systemic beta blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.
Mydriasis resulting from concomitant use of ophthalmic beta blockers and adrenaline (epinephrine) has been reported occasionally.
Beta blockers may increase the hypoglycaemic effect of antidiabetic medicinal products. Beta blockers can mask the signs and symptoms of hypoglycaemia (see section 4.4).
Women of childbearing potential/contraception
Travoprost/Timolol must not be used in women of child-bearing age/potential unless adequate contraceptive measures are in place (see section 5.3).
Pregnancy
Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/newborn child.
There are no or limited amount of data from the use of Travoprost/Timolol or the individual components in pregnant women. Timolol should not be used during pregnancy unless clearly necessary.
Epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta blockers are administered by the oral route. In addition, signs and symptoms of beta blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta blockers have been administered until delivery. If Travoprost/Timolol is administered until delivery, the neonate should be carefully monitored during the first days of life.
Travoprost/Timolol should not be used during pregnancy unless clearly necessary. For information on how to reduce systemic absorption, see section 4.2.
Breast-feeding
It is unknown whether travoprost from eye drops is excreted in human breast milk. Animal studies have shown excretion of travoprost and metabolites in breast milk. Timolol is excreted in breast milk and has the potential to cause serious adverse reactions in the breast-fed infant. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta blockade in the infant. For information on how to reduce systemic absorption, see section 4.2.
The use of Travoprost/Timolol by breast-feeding women is not recommended.
Fertility
There are no data on the effects of Travoprost/Timolol on human fertility. Animal studies showed no effect of travoprost on fertility at doses up to 75 times the maximum recommended human ocular dose, whereas no relevant effect of timolol was noted at this dose level.
Travoprost/Timolol has minor influence on the ability to drive and use machines.
As with any eye drops, temporary blurred vision or other visual disturbances may occur. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machines. Travoprost/Timolol may also cause hallucinations, dizziness, nervousness and/or fatigue (see section 4.8) which may affect the ability to drive and use machines. Patients should be advised not to drive and use machines if these symptoms occur.
A topical overdose with Travoprost/Timolol is not likely to occur or to be associated with toxicity.In case of accidental ingestion, symptoms of overdose from systemic beta blockade may include bradycardia, hypotension, bronchospasm and heart failure.
If overdose with Travoprost/Timolol occurs, treatment should be symptomatic and supportive. Timolol does not dialyse readily.
Ask anything about Travoprost/Timolol 40 micrograms/ml + 5 mg/ml eye drops, solution 5 mg, 0.04 mg. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.